Novel Macrocyclic NLRP3 Inhibitors.

Autor: Mesch S; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Shannon J; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Miller D; Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K., MacLeod A; Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K., Bouché L; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Johnston HJ; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Matthews K; Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K., Paehler A; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Best S; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Guba W; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Alanine T; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Halai R; Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K., Charge L; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Garside S; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Thom S; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Incerti-Pradillos C; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., McPherson C; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Carrillo J; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., St-Gallay S; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K., Rigo P; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Schlicht S; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Hendrick AG; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Lerner C; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Piali L; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Blaising J; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Mracsko EZ; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Jaeschke G; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland., Cooper MA; Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 25. Date of Electronic Publication: 2024 Nov 25.

Die Wachholderschildlaus, Diaspis juniperi (Bouché) L. Lindinger

Autor: Reh

Publikováno v: Zeitschrift für Pflanzenkrankheiten, 1908 Jan 01. 18(2), 101-101.

Externí odkaz: https://www.jstor.org/stable/43220015

Decreased fucosylation impacts epithelial integrity and increases risk for COPD.

Autor: Swaby C; Department of Chemical and Biomolecular Engineering, Johns Hopkins Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, 21218, USA., Yeung-Luk B; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Thapa S; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Nishida K; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Wally A; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Ghosh B; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Niederkofler A; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Luk S; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Girgis M; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Keller A; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Cortez C; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Ramaswamy S; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Wilmsen K; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205., Bouché L; Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK., Dell A; Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK., Drummond MB; Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 27514, USA., Putcha N; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Haslam SM; Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK., Mathias R; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Hansel NN; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA., Sheng J; Department of Engineering, Texas A&M University Corpus Christi, Corpus Christi, TX 78412, USA., Sidhaye V; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, 21224, Maryland, USA.; Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.; Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland, 21224, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Nov 02. Date of Electronic Publication: 2023 Nov 02.

Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.

Autor: Orsi DL; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ferrara SJ; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Siegel S; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Friberg A; Nuvisan ICB GmbH, 13353 Berlin, Germany., Bouché L; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Pook E; Research and Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany., Lienau P; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Bluck JP; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Lemke CT; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Akcay G; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA., Stellfeld T; Nuvisan ICB GmbH, 13353 Berlin, Germany., Meyer H; Nuvisan ICB GmbH, 13353 Berlin, Germany., Pütter V; Nuvisan ICB GmbH, 13353 Berlin, Germany., Holton SJ; Nuvisan ICB GmbH, 13353 Berlin, Germany., Korr D; Nuvisan ICB GmbH, 13353 Berlin, Germany., Jerchel-Furau I; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA., Pantelidou C; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA., Strathdee CA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Meyerson M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics and Medicine, Harvard Medical School, Boston, MA 02115, USA., Eis K; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Goldstein JT; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: jgold@broadinstitute.org.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2023 Jan 15; Vol. 78, pp. 117130. Date of Electronic Publication: 2022 Dec 13.

BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe.

Autor: Günther J; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Hillig RC; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Zimmermann K; Research & Development, Pharmaceuticals, Bayer Pharma AG, Aprather Weg 18a, 42113Wuppertal, Germany., Kaulfuss S; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Lemos C; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Nguyen D; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Rehwinkel H; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Habgood M; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, OxfordshireOX14 4RZ, U.K., Lechner C; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Neuhaus R; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Ganzer U; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany., Drewes M; Research & Development BCS, Bayer AG, Alfred-Nobel-Strasse 50, 40789Monheim, Germany., Chai J; School of Life Sciences, Tsinghua University, 100084Beijing, China., Bouché L; Research & Development, Pharmaceuticals, Bayer Pharma AG, Müllerstrasse 178, 13353Berlin, Germany.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Nov 10; Vol. 65 (21), pp. 14366-14390. Date of Electronic Publication: 2022 Oct 19.